Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Linder Ekberg K,
Keywords: telotristat, carcinoid syndrome, metastasized GI-NET,
#2996 A Head-to-Head Comparison between Two Software Packages for Hybrid Dosimetry after PRRT
Introduction: The number of dosimetry studies after PRRT is increasing, yet different methodologies are used which challenge comparison or pooling of results.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Huizing D, Peters S, Versleijen M, Martens E, Verheij M,
Keywords: dosimetry, PRRT, quantification,
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) represent a heterogenous group of tumours. The molecular mechanisms which contribute to progression of SI-NETs are poorly elucidated. They are considered to be molecularly distinct from neuroendocrine carcinomas (NECs), which share oncogenic pathways with adenocarcinomas.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Samsom K
Authors: Samsom K, van Veenendaal L, Roepman P, Kodach L, Steeghs N,
Keywords: whole genome sequencing, neuroendocrine tumour, small intestine, genetics,
Introduction: In PRRT for NET, feasibility of lesion uptake quantification in Lu-177-DOTATOC SPECT/CT for therapy monitoring remains unclear.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Galler M, Schatka I, Buch F, Bluemel S, Jann H,
Keywords: Lu-177-DOTATOC, PRRT, NET, dosimetry, SPECT/CT, Quantification,
Introduction: Assessment of disease status remains the fundamental basis in the management of gastro-entero-pancreatic neuro-endocrine tumors (GEPNETs). Circulating molecular information might be used as a liquid biopsy to predict its clinical course.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: van Treijen M
Authors: van Treijen M, van der Zee D, Heeres B, Staal F, Vriens M,
Keywords: biomarker, progression-free survival, gastro-entero-pancreatic neuroendocrine tumours,